Objective：The aim of this study was to analysis raltitrexed by the safety and ef icacy of intra-arterial infusion chemotherapy. Methods：Forty-seven cases in dif erent parts of cancer patients, interventional methods...Objective：The aim of this study was to analysis raltitrexed by the safety and ef icacy of intra-arterial infusion chemotherapy. Methods：Forty-seven cases in dif erent parts of cancer patients, interventional methods, based on digital subtraction angiography （DSA） prompt, raltitrexed-based chemotherapy, the tumor nourish artery infusion chemotherapy. Patients with postoperative chemotherapy side ef ects and complications, and ef icacy assessments. Results：Forty-seven patients, 2 patients had II-III degree of bone marrow suppression, the rate was 4.26%, 34 cases of I to II degree gastroin-testinal reactions, 1 case of grade III gastrointestinal reactions, the incidence of 2.13%, and 1 case mild diarrhea. I degrees or more chemotherapy-related adverse reactions did not occur in this group of patients. Al patients received at least 2 times arterial infusion chemotherapy, complete remission （CR） 3 cases, partial remission （PR） 11 cases, stable disease （SD） 17 cases, disease progression （PD） 6 cases, total ef ective rate of treatment 87.23%. Conclusion：Raltitrexed for intra-arterial chemotherapy is safe and ef ective. However, due to the smal number of this group of patients, time is short, its safety, ef-ficacy and long-term ef icacy needs further observation and validation.展开更多
文摘Objective：The aim of this study was to analysis raltitrexed by the safety and ef icacy of intra-arterial infusion chemotherapy. Methods：Forty-seven cases in dif erent parts of cancer patients, interventional methods, based on digital subtraction angiography （DSA） prompt, raltitrexed-based chemotherapy, the tumor nourish artery infusion chemotherapy. Patients with postoperative chemotherapy side ef ects and complications, and ef icacy assessments. Results：Forty-seven patients, 2 patients had II-III degree of bone marrow suppression, the rate was 4.26%, 34 cases of I to II degree gastroin-testinal reactions, 1 case of grade III gastrointestinal reactions, the incidence of 2.13%, and 1 case mild diarrhea. I degrees or more chemotherapy-related adverse reactions did not occur in this group of patients. Al patients received at least 2 times arterial infusion chemotherapy, complete remission （CR） 3 cases, partial remission （PR） 11 cases, stable disease （SD） 17 cases, disease progression （PD） 6 cases, total ef ective rate of treatment 87.23%. Conclusion：Raltitrexed for intra-arterial chemotherapy is safe and ef ective. However, due to the smal number of this group of patients, time is short, its safety, ef-ficacy and long-term ef icacy needs further observation and validation.
